Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
The recommendation is based on results from the phase
Texas Instruments Incorporated (NASDAQ: TXN) shares are falling after the company reported lower-than-expected third-quarter sales results and issued fourth-quarter